Previous 10 | Next 10 |
Well, in principle we have deals across the board. The U.S. government and Federal Reserve are set to start pumping trillions of dollars into the economy. Whether it’s through quantitative easing or sending checks in the mail, money is starting to flow. So what does this mean for the mark...
LA JOLLA, CA / ACCESSWIRE / March 23, 2020 / Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that it will be presenting at the 2020 Spring Investor Summit being held on...
LA JOLLA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that Gregory D. Gorgas, President and Chief Executive Officer ...
Schmitt Industries (NASDAQ: SMIT ) -20% as it intends to delist and deregister common stock from the Nasdaq. More news on: Schmitt Industries, Inc., Rockwell Medical, Inc., Micro Focus International plc, Stocks on the move, , Read more ...
Gainers: OpGen (NASDAQ: OPGN ) +49% . More news on: OpGen, Inc., Insmed Incorporated, Artelo Biosciences, Inc., Stocks on the move, , Read more ...
Artelo Biosciences (NASDAQ: ARTL ) +63% on NCI grant of $4.2M to Stony Brook University to advance FABP5 inhibitor cancer program. More news on: Artelo Biosciences, Inc., Insmed Incorporated, CTI BioPharma Corp., Stocks on the move, , Read more ...
FABP5 platform under exclusive license to Artelo Biosciences NCI support provides further validation of next-generation target for cancer therapeutics LA JOLLA, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical c...
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held on ...
Artelo Biosciences (NASDAQ: ARTL ): Q1 GAAP EPS of -$0.40. Cash and cash equivalents of $3.37M Press Release More news on: Artelo Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
LA JOLLA, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the first qua...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...